Mr Koki Ohashi
COMPANY PRESCRIPTION;
Kissei America, Inc is the US subsidiary of Kissei Pharma, one of the Japanese medium-sized pharma companies spending about 20% of revenue to its R&D effort.
Kissei is actively seeking for in-licensing, out-licensing and other business development opportunities for new drugs.
For in-licensing, Kissei's primary focus is the territory of Japan and the therapeutic fields of urology, dialysis management/kidney disease, women's health, opthalmology and certain diseases with unmet medical needs.
For out-licensing, Kissei is actively seeking partners for several new chemical entities for the territory outside Japan. Such out-licensing opportunities include agents for endometriosis/fibroid, diabetes, Parkinson's disease, gout/hyperuricemia and kidney stone in various stage of development.
PIPELINE PRODUCT;
1. NAME ; Mitiglinide
DESCRIPTION ; Mitiglinide is a short-acting insulin secretagogue for type II diabetes. The
agent has been already on the market in Japan and some Asian countries.
The product is available for licensing in certain countries outside Asian
countries.
PHASE ; Market
INDICATION ; Type II diabetes
2. NAME ; Remoglifozin
DESCRIPTION ; Remogliflozin is an SGLT2 inhibitor available for licensing in certain
countries.
PHASE ; Phase ll, lla, llb
INDICATION ; Diabetes
3. NAME; KUL-7211
DESCRIPTION ; KUL-7211 is a beta 2/3 dual agonist, targeting the facilitation of kidney
stone passage, available for licensing.
PHASE ; Phase ll, lla, llb
INDICATION ; Kidney Stone
4. NAME ; KLH-2109
DESCRIPTION ; KLH-2109 is on oral GnRH antanogist available for licensing
PHASE ; Phase ll, lla, llb
INDICATION ; Endometriosis, Uterine Fibroids
5. NAME ; KGA-3235
DESCRIPTION ; KGA-3235 is an SGLT1 inhibitor available for licensing in certain Asian
countries.
PHASE ; Phase l
INDICATION ; Diabetes
6. NAME ; KOM-1962
DESCRIPTION ; KOM-1962 is a novel and improved COMT inhibitor available for
licensing.
PHASE ; Preclinical
INDICATION ; Parkinson’s Disease
7. NAME ; KUX-0511
DESCRIPTION ; KUX-0511 is the agent to be developed for gout and hyperuricemia
through decreasing formation of uric acid and uricosuric effect, and
available for licensing.
PHASE ; Phase l
INDICATION ; Gout and Hyperuricemia
